Alnylam Pharmaceuticals
ALNY
#618
Rank
HK$252.30 B
Marketcap
HK$1,949
Share price
3.59%
Change (1 day)
73.12%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -HK$32.20

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -HK$31.88. In 2022 the company made an earnings per share (EPS) of -HK$72.06 a decrease over its 2021 EPS that were of -HK$55.85.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-HK$32.20-55.32%
2022-HK$72.0629.03%
2021-HK$55.85-3.36%
2020-HK$57.79-8.48%
2019-HK$63.147.67%
2018-HK$58.6439.74%
2017-HK$41.9612.94%
2016-HK$37.1638.84%
2015-HK$26.76-32.88%
2014-HK$39.87259.44%
2013-HK$11.09-31.25%
2012-HK$16.1352.94%
2011-HK$10.5530.77%
2010-HK$8.07-8.77%
2009-HK$8.8478.13%
2008-HK$4.96-70.78%
2007-HK$16.9999.09%
2006-HK$8.53-43.88%
2005-HK$15.20-82.33%
2004-HK$86.05-59.23%
2003-HK$211.06

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-HK$13.19-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$289.79-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$60.74 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$2.09-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$13.11-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$29.01-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
HK$24.67-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-HK$15.51-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel